Research programme: Apolipoprtotein A-1 multimer therapeutics - ABIONYX Pharma
Alternative Names: CargomerLatest Information Update: 28 Dec 2022
At a glance
- Originator Cerenis Therapeutics
- Developer ABIONYX Pharma
- Class Apolipoprotein therapeutics; Multiprotein complexes
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in France (SC)
- 13 Nov 2018 Preclinical trials in Cancer in France (SC)
- 13 Nov 2018 Preclinical pharmacodynamics data in Cancer presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018)